Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effimia (norgestimate + ethinylestradiol) cycle control and tolerability study in Italy
2021-003027-15Phase 4Active
- Sponsor
- Italfarmaco
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of norgestimate + ethinyl estradiol in menstrual disorders, sponsored by Italfarmaco. Primary endpoint: Primary efficacy outcome. Started Nov 2022; status: active.
02
Drugs
norgestimate + ethinyl estradiol
03
Conditions
menstrual disorders
Beyond the preview
Go deeper on 2021-003027-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003027-15.